Refractory Crohn's Disease: Effective Therapy by Inhibition of Interleukin 12 and Interleukin 23
This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...